CAS No. |
1318074-25-7 |
|---|---|
中文名称 |
(3aR,4R,7S,7aS)-2-(((1R,2R)-2-((4-(苯并[d]异噻唑-3-基)哌嗪-1-基)甲基)环己基)甲基)六氢-1H-4,7-亚甲基异吲哚-1,3(2H)-二酮 |
英文名称 |
(3aR,4R,7S,7aS)-2-(((1R,2R)-2-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione |
别名 |
R,R-endo-lurasidone HCl;(3aR,4R,7S,7aS)-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione;4,7-Methano-1H-isoindole-1,3(2H)-dione,2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-methyl]cyclohexyl] methyl]hexahydro-,(3aR,4R,7S,7aS);endo-Lurasidone;lurasidone-23;Lurasidone impurity 25/(3aR,4R,7S,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole- 1,3(2H)-dione;Lurasidon hydrochloride iMpurity27;Endo Lurasidone Hydrochloride |
标准英文名 |
(3aR,4R,7S,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione |
MDL No. |
MFCD28404650 |
分子式 |
C28H36N4O2S |
分子量 |
492.69 |
精确分子量 |
492.26 |
SMILES |
O=C1N(C[C@H]2[C@H](CN3CCN(C4=NSC5=CC=CC=C45)CC3)CCCC2)C([C@]6([H])[C@](C7)([H])CC[C@]7([H])[C@]16[H])=O |
标准SMILES |
O=C1[C@H]2[C@H]([C@@H]3C[C@H]2CC3)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C21 |
性状 |
Solid |
用途 |
For laboratory research purposes. Not for drug or household use. |
信号词 |
Warning |
InChIKey |
PQXKDMSYBGKCJA-GGYSQDOYSA-N |
危险类别(旧) |
H302,H315,H319,H335 |
存储要求 |
Sealed in dry, 2-8°C,Keep container tightly closed in a dry and well-ventilated area. Containers which are opened must be carefully resealed and kept upright to prevent leakage. |
危险品分类 |
Acute toxicity, oral (Category 4),Skin corrosion/irritation (Category 2),Serious eye damage/eye irritation (Category 2A),Specific target organ toxicity, single exposure; Respiratory system (Category 3) |
|---|---|
化学稳定性 |
Stable under recommended storage conditions. |
符号 |
|
|
|
评论 |
|---|